1. Schwandt, P. (1982) inTherapeutic Selectivity and Risk/Benefit Assessment of Hypolipidemic Drugs (Ricci, G., Paoletti, R., Pocchiari, F., and Poggiolini, D., eds.) pp. 29–32, Raven Press, New York, NY.
2. Witiak, D.T., Newman, H.A.I., and Feller, D.R. (1977)Clofibrate and Related Analogues. A Comprehensive Review, Medical Research Series, Vol. 7, pp. 54–140, Marcel Dekker, New York, NY.
3. O'Brien, M., Patel, S.T., Mukhopadhyay, A., Newman, H.A.I., Feller, D.R., Kokrady, S.S., Witiak, D.T., Lanese, R.R., and Rice, J.C. (1981)Lipids 16, 903–911.
4. Baldwin, J.R., Witiak, D.T., and Feller, D.R. (1980)Biochem. Pharmacol. 29, 3143–3154.
5. Witiak, D.T., Kokrady, S.S., Patel, S.T., Huzoor-Akbar, Feller, D.R., and Newman, H.A.I. (1982)J. Med. Chem. 25, 90–93.